Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
BMO Capital Reiterates Outperform on Pfizer (PFE) Following 4Q
February 3, 2016 8:21 AM ESTBMO Capital maintained an Outperform rating on Pfizer (NYSE: PFE), and cut the price target to $39.00 (from $41.00), following the company's 4Q earnings report. Good operational revenue growth drove a 3% top-line beat. The company's better-than-expected gross margin was offset by higher opex, but the lower tax rate helped drive the bottom-line penny beat. 2016 forecasts are below consensus, but BMO believes that the Street estimates will likely come down soon.
Analyst... More
Portola Pharma (PTLA) Enters Licensing Agreements for Investigational Agent Andexanet in Japan (BMY) (PFE)
February 1, 2016 6:56 AM ESTPortola Pharmaceuticals (Nasdaq: PTLA), announced that it has licensed lead development and commercial rights to its investigational agent andexanet alfa in Japan to Bristol-Myers Squibb Company and Pfizer Inc. to be developed as an antidote for apixaban and other Factor Xa inhibitors. Separately, Portola has entered into a clinical collaboration agreement with Bayer HealthCare to include its Factor Xa inhibitor rivaroxaban in this clinical development program in Japan.
Three oral Factor Xa inhibitors are currently on the market in Japan Bristol-Myers Squibb and Pfizers apixaban, Bayer HealthCares rivaroxaban, and Daiichi Sankyos... More
